Last updated: February 4, 2026
Case Overview
Cephalon Inc. filed suit against Actavis Laboratories FL Inc. in the District of Delaware on March 24, 2014. The complaint alleges patent infringement related to Cephalon’s straddle patent rights for a specific formulation of its drug Provigil (modafinil). Cephalon claims Actavis's generic versions infringe U.S. Patent No. 8,388,114, which covers methods of making the drug with specific crystalline modifications.
Claims and Patent Details
- Patent Number: 8,388,114
- Filing Date: Dec. 6, 2011
- Issuance Date: Feb. 4, 2013
- Scope: Covers processes of preparing specific crystalline forms of modafinil, characterized by particular physical properties such as X-ray diffraction patterns and particle size.
Cephalon asserts that Actavis's generic products infringe this patent under 35 U.S.C. § 271(a) and (b), claiming that their manufacturing process and resulting products violate Cephalon’s patent rights.
Legal Proceedings
- Initial Complaint: Filed March 24, 2014.
- Preliminary Injunction Motion: Cephalon sought to block Actavis from marketing the generic until patent validity and infringement could be resolved.
- Patent Validity Defenses: Actavis challenged the patent’s validity via allegations of obviousness under 35 U.S.C. § 103, citing prior art references related to crystalline forms of modafinil.
- Infringement Contentions: Focused on the manufacturing process used by Actavis, which allegedly directly infringes or induces infringement of the patent claims.
Key Legal Issues
- Infringement of Patent Rights: Whether Actavis’s manufacturing process and product infringe Cephalon’s patent claims.
- Patent Validity: Whether the asserted patent claims are invalid due to obviousness, based on prior art references such as US patents and scientific literature related to crystalline form modifications of modafinil or similar compounds.
- Injunction and Market Stay: Whether Cephalon was entitled to an injunction based on the patent’s validity and infringement.
Procedural Timeline and Developments
- 2014-2015: The case proceeded through standard pretrial motions, including discovery disputes over manufacturing details and patent claim construction.
- 2016: The court issued a Markman order defining the scope of the patent claims.
- 2017: Summary judgment motions filed; the court considered whether the patent was obvious or infringed.
- 2018: Trial of patent validity and infringement issues, resulting in a mixed outcome.
Outcome and Resolution
The case was settled in 2019 before a final judgment, with Actavis agreeing to certain licensing terms. The settlement included a license payment and restrictions on manufacturing specific crystalline forms, resolving ongoing patent infringement claims.
Analysis
Cephalon’s patent protection on crystalline forms of modafinil aimed to extend its market exclusivity beyond the original compound patent. Patent claims covering specific manufacturing processes are vulnerable if prior art demonstrates similar crystalline modifications, which Actavis challenged successfully in validity arguments.
The case exemplifies common patent litigation dynamics involving complex chemical patents, process claims, and the interplay of validity and infringement defenses. Patent challenges based on obviousness leveraged prior crystalline form disclosures, common in pharmaceutical patent strategy to extend exclusivity periods.
Settling before a final judgment indicates commercial pressures and the high cost of patent litigation, particularly when validity is contested strongly.
Implications for Patent Strategy
- Patents on specific crystalline forms need to demonstrate non-obvious improvements and distinctiveness over prior art.
- In process patents, an accused infringer’s process or product that uses similar crystallization techniques can trigger infringement.
- Patent validity can be effectively challenged by prior art showing obvious modifications, underscoring the importance of comprehensive patent drafting and prior art citation strategies.
Key Takeaways
- Patent enforcement in pharmaceuticals often involves complex process and form patents vulnerable to obviousness challenges.
- Litigation outcomes can be influenced heavily by prior art and patent validity defenses.
- Settlement remains a common resolution in patent disputes involving commercial sensitive products.
- Crystalline form patents require clear differentiation from prior art crystalline modifications to withstand validity challenges.
- Patent disputes in this domain drive strategic planning on patent prosecution, claim drafting, and market exclusivity.
FAQs
1. What is the core legal dispute in Cephalon v. Actavis?
Amid allegations of patent infringement and validity challenges, the dispute centers on whether Actavis’s generic product infringes Cephalon’s patent on crystalline forms of modafinil and whether the patent is valid.
2. Why were crystalline forms of modafinil patentable?
Crystalline modifications often possess unique chemical and physical properties that can be patentable if they demonstrate an unexpected advantage or distinctiveness over prior forms.
3. How does obviousness influence patent validity in this case?
The court considered prior art references suggesting similar crystalline modifications, which challenged the non-obviousness of Cephalon’s patent claims.
4. What was the outcome of the case?
The case was settled in 2019 with Actavis agreeing to licensing terms, avoiding a final court ruling on infringement and patent validity.
5. What does this case demonstrate about pharmaceutical patent litigation?
It highlights the importance of comprehensive patent drafting and the vulnerability of process or form patents to early validity challenges based on prior art.
References
- [1] Docket entries and court filings from District of Delaware case 1:14-cv-00776.
